[Form 4] Strata Critical Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Strata Critical Medical, Inc. (SRTA): Director and Co-CEO/CFO William A. Heyburn reported equity changes on Form 4. On 10/31/2025, he acquired 181,072 shares of Class A common stock at $0 upon the Compensation Committee’s certification of performance criteria for PSUs granted on March 8, 2024. Following this, his beneficial ownership was 1,486,569 shares (direct).

On 11/03/2025, 100,133 shares were disposed of at $5.03 under transaction code “F,” reflecting shares withheld by the issuer to satisfy tax withholding obligations related to the PSU vesting. After these transactions, his beneficial ownership stood at 1,386,436 shares (direct).

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heyburn William A.

(Last) (First) (Middle)

C/O STRATA CRITICAL MEDICAL, INC.

31 HUDSON YARDS, 14TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
10/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A common stock, $0.0001 par value per share	10/31/2025		A		181,072(1)	A	$0	1,486,569	D
Class A common stock, $0.0001 par value per share	11/03/2025		F		100,133(2)	D	$5.03	1,386,436	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that were acquired upon the certification of the Compensation Committee of the Issuer's Board of Directors of the satisfaction of performance criteria underlying an award of performance-based restricted stock units ("PSUs") granted to the Reporting Person on March 8, 2024.

2. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of PSUs.

Remarks:

	/s/ Melissa M. Tomkiel, as attorney-in-fact for William A. Heyburn	11/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SRTA’s William A. Heyburn report on Form 4?

He reported acquiring 181,072 shares at $0 on 10/31/2025 from PSU vesting and a tax withholding disposition of 100,133 shares at $5.03 on 11/03/2025.

Why were 100,133 SRTA shares disposed at $5.03?

They were withheld by the issuer to satisfy tax withholding obligations related to PSU vesting.

What is Heyburn’s role at Strata Critical Medical (SRTA)?

He is a Director and serves as Co-CEO and CFO.

What is Heyburn’s SRTA share ownership after the reported transactions?

He directly owns 1,386,436 shares following the transactions.

What triggered the 181,072-share acquisition at $0 for SRTA?

The Compensation Committee certified the performance criteria for PSUs granted on March 8, 2024.

What security class was involved in the SRTA Form 4?

The transactions involved Class A common stock, par value $0.0001 per share.